Is LBRX undervalued? Our fair value estimate
LB Pharmaceuticals Inc · Healthcare · NGM
Price as at 1 Oct 2026, 11:46 UTC. Quotes are delayed.
How we got here
The estimate is computed from LBRX's reported fundamentals, with a growth assumption that is deliberately capped: small changes to an uncapped growth or terminal assumption can justify any price, and a number that can justify anything means nothing. These are the inputs the model holds for LBRX today; the exact method, and where it goes wrong, is on the methodology page.
Wall Street's published earnings growth forecast, used as context for the capped growth assumption, never swallowed whole.
Persistent high returns on capital are what a moat looks like in the accounts, and they feed the moat score alongside the valuation.
Leverage haircuts the estimate: debt claims cash before shareholders do, and it turns bad years into dangerous ones.
Wall Street's number, next to ours
The mean analyst price target for LBRX is $45.00 across 7 analysts, which implies +17.2% from the current price. Our estimate is $13.21. They answer different questions: an analyst target is a 12-month price prediction averaged across banks; ours is a model's view of what the business is worth, with every assumption published. When they disagree, at least one of us is wrong.
The belief gap: what growth this price asks you to believe
Run a discounted cash flow backwards and every price becomes a growth assumption. One axis compares them: today's market price, the entry prices implied by super investors' 13F filings, the mean analyst target, and the growth our own model funds. The gap between the market's marker and the cohort's markers is the growth you are being asked to believe that informed buyers did not need.
No growth rate between 0% and 30% makes our model's fair value equal today's price, so the market is pricing something this model cannot express. Citadel Advisors's Q4 2025 entry underwrote about 17.7%. Our model funds 5.0%.
Citadel Advisors's Q4 2025 filing implies an average entry near $22.26, which implied about 17.7% annual growth under our model (low confidence).
Millennium Management's Q3 2025 filing implies an average entry near $15.79, which implied about 9.2% annual growth under our model.
Marshall Wace's Q3 2025 filing implies an average entry near $15.79, which implied about 9.2% annual growth under our model.
Two Sigma Investments's Q3 2025 filing implies an average entry near $15.79, which implied about 9.2% annual growth under our model.
Entry prices are filing-implied averages (reported position value divided by reported shares for the quarter a position was opened or materially increased), not actual cost bases; 13Fs lag by up to 45 days. How the Belief Gap is computed.
Healthcare peers, by our rating
The same model, run on the highest-rated names in the same sector. A gap to fair value is only comparable when the method behind it is identical, which here it is.
Common questions
Is LB Pharmaceuticals Inc (LBRX) undervalued?
On our model, LBRX at $38.38 trades 66% above our fair value estimate of $13.21, so it screens as overvalued today. That is one model's answer, not a recommendation: a fair value estimate is an argument about the future, and the market is frequently right about why something is cheap.
What is the fair value of LBRX?
Our current fair value estimate for LB Pharmaceuticals Inc is $13.21 per share. For comparison, the mean Wall Street analyst price target is $45.00 across 7 analysts; that is their number, computed differently from ours. The estimate moves as prices and fundamentals move.
How is LBRX's fair value calculated?
From LB Pharmaceuticals Inc's reported fundamentals: earnings power, a deliberately capped growth assumption, and a discount for balance sheet and volatility risk. The full method, including its known weaknesses, is published on our methodology page, and the interactive Valuation Lab lets you change every assumption and watch the value move.
Disagree with an assumption? Good. The Valuation Lab on the LBRX app page restates this estimate as a separate five-year discounted cash flow, puts its growth and discount rates on sliders, and runs it backwards to show the growth the market is currently pricing in.
A fair value estimate is a model output computed from company filings and market data, refreshed daily; quotes are delayed. It is educational information, not financial advice and not a recommendation to buy or sell anything. Read the full disclaimer.